CME Internet Symposium

Theme_Banner_CROI_2022_v2

 

 

CROI_Launch_Demand_button

 

 

About the Program

Program Overview

The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 29th Conference on Retroviruses and Opportunistic Infections (CROI 2022). This program consists of two components: (1) CME Internet Symposium: CROI 2022 Expert Review: a 1.5-hour Internet symposium that features an overview of key presentations and posters, selected by the expert faculty; and (2) CROI 2022 e-Newsletter: a brief on-line summary of the most essential data presented at the conference.

The CME Internet Symposium: CROI 2022 Expert Review will feature a panel of HIV experts reviewing and discussing key presentations on antiretroviral therapy presented at CROI 2022. The review and discussion will focus on HIV therapeutic options and developments, including: current treatment and management strategies, algorithms and recommendations, therapies in development, epidemiology, and diagnosis and clinical management of specific patient populations. This activity will enable participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All online components of the program can be accessed at www.viraled.com.

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at CROI 2022 and it is not sanctioned by the organizers of CROI 2022. 

Back to Top

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top

Learning Objectives

After completing these activities, participants should be better able to:

  • Describe and apply in a clinical setting the most current HIV prevention and treatment approaches and paradigms
  • Improve retention of patients on ARV therapy by addressing ARV side effects that can interfere with adherence to ARV regimens
  • Support the rapid initiation of appropriate and effective antiretroviral therapy
  • Characterize new antiretroviral agents in development and how they may be used in the treatment of people with HIV infection

Release Date: March 2, 2022

Expiration Date: March 2, 2023

Estimated time to complete the program: 30 minutes per module

Media: Internet

Back to Top


Faculty

José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain

Marta Boffito, MD, PhD, FRCP
Clinical Research Lead, Clinical Research Facility
Consultant Physician and HIV Service Director
Chelsea & Westminster Hospital
Professor, Imperial College London
London, United Kingdom 

Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom 

Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine
University Hospital
Bonn, Germany

Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois 

Back to Top

Joint Accreditation Statement

Jointly-Accredited-Provider-TM_1000x636

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation

Module 1 (Co-infections: Hepatitis C and COVID-19):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 2 (HIV Prevention and Cure):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 3 (Anitretroviral Treatment): 
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 4 (Adverse Events and Co-morbidities):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 5 (Pregnancy and Pharmacology):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 


Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the content of this CME activity:

Jose Arribas, MD

  • Grant/Research Support: ViiV, Gilead
  • Consultant/Advisory Board: ViiV, GSK, Janssen, Gilead, MSD, Aelix

Marta Boffito, MD

  • Consultant/Advisory Board: ViiV, MSD, Mylan, Gilead, Cipla, GSK
  • Grant/Research Support: ViiV, Roche, MSD, Mylan, Valneva, Novavax, Gilead
  • Speakers Bureau/Honoaria fornon-CME: ViiV, Gilead

Ian Frank, MD

  • Consultant/Advisory Board: Gilead, GSK, Johnson & Johnson, ViiV
  • Grant/Research Support: Johnson & Johnson, Moderna, Sanofi Genzyme, Pfizer
Graeme Moyle, MD

 

  • Consultant/Advisory Board: Gilead, Merck, Theratechnologies, ViiV, Novartis
  • Speakers Bureau/Honoraria for non-CME: Gilead, Merck, Theratechnologies, ViiV
  • Grant/Research Support: NEAT Foundation, Gilead, Merck, Theratechnologies, ViiV

Juergen Rockstron, MD

  • Consultant/Advisory Board: Gilead, Janssen, Merck, Theratechnologies, ViiV
  • Speakers Bureau/Honoraria for non-CME: Abivax, Galapagos, Gilead, Merck, Janssen, ViiV

Renslow Sherer, MD

  • Contracted Research: Gilead

The PIM planners and others have nothing to disclose.  The ViralEd, Inc. planners and othes have nothing to disclose.
Back to Top

Method of Participation and Request for Credit

1) Go to http://www.cmeuniversity.com/

2) Login or Create a New Account (will take less than 1 minute)
   a) If you receive a message when creating a new account that "the email you entered is already in use", please click the Forgot my Username or Password link to have your Username and Password sent to you via email
   b) After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
3) Type in 17099 at the top of the page, "Find Post-Test/Evaluation by Course", and click enter
4) Click on the activity title when it appears
5) Choose the type of credit you desire
6) Complete the online Evaluation
7) Receive an immediate CE Certificate to download and/or print for your files

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Back to Top

Computer System Requirements

This program requires HTML 5 enabled web browsers such as; Microsoft Edge, Mozilla Firefox, Apple Safari or Google Chrome.

Back to Top

 

    PIM_small    VE logo 300px

 

 

This activity is supported by independent educational grants from Gilead Sciences Medical Affairs and Janssen Therapeutics, Division of Janssen Products LP

This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.

 

 

 

Back to Top

 

     

Prepare to print

Share this page:

Get link code to this page     


Back to Top